How Menopause Reshapes Your Gut Health and Disease Risk
Menopause alters gut motility, microbiota, and liver health — raising risks for GI conditions and complicating existing diseases.
Summary
A 2025 review in Nature Reviews Gastroenterology & Hepatology examines how menopause affects the gastrointestinal tract. The hormonal shifts of peri- and postmenopause alter gut motility, change gut microbiota composition, and increase susceptibility to several GI and liver conditions. Women with pre-existing GI diseases may experience worsening symptoms during this transition. Hormone replacement therapy, while helpful for menopausal symptoms, carries its own GI implications. Additionally, medications used to treat GI conditions — such as glucocorticoids — can compound the bone loss risk already elevated by menopause. The authors highlight a critical research gap: despite menopause being universal among people who menstruate, very few studies have rigorously evaluated its impact on GI health and quality of life.
Detailed Summary
Menopause is a universal biological transition, yet its impact on gastrointestinal health remains surprisingly understudied. A comprehensive 2025 review published in Nature Reviews Gastroenterology & Hepatology addresses this gap, synthesizing available evidence on how menopause affects the gut, liver, and related conditions.
The hormonal changes of menopause — primarily the loss of estrogen and progesterone — directly influence gastrointestinal function. These hormones modulate gut motility, and their decline can lead to altered bowel habits, slower transit times, and increased GI symptoms. The gut microbiome also shifts during this transition, with postmenopausal microbiota profiles diverging significantly from premenopausal ones, potentially influencing systemic inflammation and metabolic health.
Several GI and hepatic conditions become more prevalent or more severe during peri- and postmenopause. Conditions such as irritable bowel syndrome, inflammatory bowel disease, and non-alcoholic fatty liver disease may worsen or emerge during this window. Women managing these conditions before menopause often report greater symptom burden and reduced quality of life as they transition.
The interplay between GI medications and bone health adds another layer of complexity. Glucocorticoids and immunosuppressants used to manage conditions like Crohn's disease or celiac disease can accelerate bone loss — compounding the osteoporosis risk already heightened by declining sex hormones. Celiac disease itself impairs calcium absorption, further raising secondary osteoporosis risk.
Hormone replacement therapy (HRT), commonly prescribed for menopausal symptoms, also has GI implications that are not fully characterized. The authors call for more dedicated research into how HRT affects gut function and disease outcomes. Overall, this review serves as both a clinical resource and a call to action for researchers to prioritize menopausal GI health.
Key Findings
- Menopause alters gut motility and microbiota composition, potentially worsening GI symptoms in peri- and postmenopausal women.
- Pre-existing GI conditions like IBD and IBS may become more severe and reduce quality of life during menopause.
- GI medications such as glucocorticoids compound menopausal bone loss, raising secondary osteoporosis risk.
- Hormone replacement therapy may influence GI health, though evidence remains limited and under-studied.
- Despite menopause being universal, dedicated research on its GI effects is critically lacking.
Methodology
This is a narrative review published in Nature Reviews Gastroenterology & Hepatology, synthesizing existing literature on the intersection of menopause and GI health. The authors are gastroenterologists at the University of Wisconsin and drew from available clinical and mechanistic studies. No primary data were generated; conclusions are limited by the breadth and quality of existing evidence.
Study Limitations
This review is limited to available literature, which the authors themselves note is sparse and often not designed to isolate menopausal effects on GI outcomes. Much of the evidence is observational, limiting causal inference. Gaps in diverse population representation and longitudinal data further constrain the conclusions drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: